pharma news today obesity drugs glp-1 september 2025 Agonists Weight Loss Market Report, 2025-2030 Drugmakers are racing to find

25 , 26 Metaanalyses have found no evidence that GLP1RAs exacerbate psychotic symptoms

Recently, Eli Lilly reported they anticipate submitting Orforglipron for FDA approval in the second half of 2025, with potential availability shortly after if approved

Achieving a healthier weight can help support those goals, but wellness always includes more than a number on the scale

[1] [2] If you experience severe, persistent abdominal pain, seek immediate medical evaluation

Advertisement Procedure offers potential for less pain and faster recovery in selected patients Challenges include multimorbidity, polypharmacy, limited mobility and sarcopenia Data could help inform policy and patient-provider conversations Pheochromocytoma case underscores the value in considering atypical presentations Advocacy group underscores need for multidisciplinary expertise A review of the latest evidence about purported side effects High-volume surgery center can make a difference Advancements in equipment and technology drive the use of HCL therapy for pregnant women with T1D

Looking forward to connecting with more people working in bioprocess and CDMO spaces